April 2019
Winner of the Let’s Go France trophy in the category “France, a model of sustainable economy”
We are multicultural,
creative & collectively
striving to impact
global health
Our strength is our people
Since our creation, the know-how and strong involvement of our people have been essential elements in our development. Our 130 employees, representing more than 20 nationalities, have major holdings in our company’s stock and share a common ambition: to have a real and positive impact on global health.
All of our people are able to become shareholders soon after they start working at MedinCell. In this way, they become real partners, they are strongly involved, and their interests are clearly aligned with those of the Company.
It also helps to guarantee that our people benefit directly from the Company’s success. Moreover, because our people are our main shareholders, we remain independent and stay focused on our mission of Better Medicine For All.
The desire to involve our people in the Company’s success has led to the development of a dynamic entrepreneurial culture at all levels of the business in the service of operational effectiveness.
What we believe
The pharmaceutical industry needs to be revolutionized.
We believe it can be done by combining purposeful innovation with a pioneering business model. One without the other will not be enough.
At MedinCell we believe we have both. With our powerful technology, we are able to develop more efficient and affordable treatments.
Our tailor-made business models are based on fairness and an appreciation for all stakeholders; patients first, but also practitioners, payers and every party associated with the pharmaceutical industry.
Innovation is worth nothing unless it’s shared. That’s why we develop new best-in-class therapeutic solutions which are globally accessible.
Conduct ethical activities in a socially & environmentally responsible manner.
Supervisory Board
Anh NguyenChairmanDr Anh Nguyen, co-founder and Chairman of the Company’s Supervisory Board, is an experienced biotechnology entrepreneur. He co-founded Syntro, first listed on NASDAQ in 1987, and Invitrogen, first listed on NASDAQ in 1999, which later became Life Technologies and was acquired by ThermoFisher in 2013 for US$16 billion. Anh Nguyen is a molecular biologist with a PhD from the University of California at San Diego, and also completed the MBA program at the MIT Sloan School of Management.
Sabri MarkabiVice-ChairmanA specialist in neuroscience and a graduate in pharmacology, Dr Sabri Markabi has spent more than twenty-five years in international positions in the pharmaceutical industry. In particular, he led the clinical neuroscience department and supervised the development of the ophthalmology unit at Novartis before heading up R&D at the Alcon pharmaceutical company from 2008 to 2015. During his career, Sabri Markabi has taken part in or chaired many corporate governance bodies in private or listed companies. Since 2015, he has advised many companies, specifically regarding their investment strategy and R&D.
Philippe GuyDuring his 31 years with the Boston Consulting Group, Philippe advised several international companies in the pharmacy, biotechnology and medical device sectors in several areas, including Corporate Strategy and Business Units, Research and Development, Marketing and Manufacturing as well as Large-Scale Transformation and Integration following mergers/acquisitions. Previously, Philippe Guy was Global Head of Health Practice at BCG from 1997 to 2006. As a member of the Executive Committee of BCG, he was responsible for all BCG’s practices from 2003-2006. Philippe Guy is a graduate of the prestigious HEC (Hautes Etudes Commerciales) business school.
Virginie LleuThe Founder and Chief Executive Officer of L3S, one of Europe’s leading life sciences research firms, Virginie Lleu held a variety of health recruitment positions before setting up her first recruitment firm specializing in healthcare in 2003, which was sold to Whitehead Mann five years later. Virginie Lleu is also a member of two Boards of Directors: La Fondation Fondamentale (foundation for scientific cooperation dedicated to combating major psychiatric disorders) and LNC (a start-up specializing in the treatment of chronic metabolic diseases, specifically pre-diabetes and obesity). With a background is in clinical psychology (graduate degree), she began her career as a neuropsychologist in leading university hospitals in Paris. Virginie Lleu is a graduate in clinical psychology and pathology (DESS).
Karine LignelRepresentative of CM-CIC InnovationKarine Lignel is the Chief Executive Officer of CM-CIC Innovation. Her field of expertise is in high-growth technology companies. Specializing in life sciences, she selected and subsequently invested in more than fifteen companies. She has held numerous positions on more than 20 Boards of Directors and Supervisory Boards and has helped managed more than 40 companies, supporting them in their strategic plans. She was involved in several rounds of refinancing and has played a key role in three industrial buyouts, as well as two successful IPOs. Karine Lignel has an engineering degree from ENSIA (agrifood business) and a Master’s degree in agrifood business management from IGIA-ESSEC.We’re always looking for new talent
Careers
The people of MedinCell aren’t just creating life-sustaining products, their aim is to revolutionize the patient’s way of life. Interested in being part of an employee-owned, creative workplace?
